Tiffany Franks
Family · Defiance, OHNPI 1477198646
Payments from drug & device makers
Across 254 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$569
- AbbVie$532
- Novo Nordisk$455
- AstraZeneca$348
- Boehringer Ingelheim$322
- Amgen$236
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,158100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 35 | $569 |
| AbbVie | 43 | $532 |
| Novo Nordisk | 25 | $455 |
| AstraZeneca | 17 | $348 |
| Boehringer Ingelheim | 17 | $322 |
| Amgen | 16 | $236 |
| Lilly USA, LLC | 14 | $217 |
| Bayer | 11 | $183 |
| Abbott | 8 | $167 |
| GSK | 10 | $159 |
| Biohaven Pharmaceuticals, Inc. | 7 | $113 |
| Novartis | 5 | $77 |
| Merck | 5 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $68 |
| Sanofi-aventis U.S. LLC | 4 | $67 |
| Johnson & Johnson | 1 | $66 |
| Lundbeck LLC | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Phadia US Inc. | 2 | $33 |
| Exact Sciences | 2 | $31 |
| Radius Health, Inc. | 2 | $31 |
| Biogen | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Mylan Specialty L.p. | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Corium, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Exeltis, USA Inc. | 1 | $13 |
| Organon | 1 | $11 |
How this compares
$4,158 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 41 | $52,692 |
| JanuviaSitagliptin Phosphate | 28 | $32,770 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $31,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $29,688 |
| EliquisApixaban | 31 | $29,381 |
| FarxigaDapagliflozin Propanediol | 21 | $26,094 |
| TrulicityDulaglutide | 11 | $14,065 |
| MounjaroTirzepatide | 12 | $11,986 |
| XareltoRivaroxaban | 14 | $8,937 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $5,148 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $4,450 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,041 |
| Atorvastatin Calcium | 255 | $2,915 |
| BreynaBudesonide/Formoterol Fumarate | 17 | $2,552 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Farxiga | $348 | $57,59055 claims |
| Novo NordiskOzempic | $455 | $52,69241 claims |
| MerckJanuvia | $69 | $32,77028 claims |
| GSKTrelegy Ellipta | $159 | $29,68835 claims |
| PfizerEliquis | $569 | $29,38131 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $217 | $26,05023 claims |
| Johnson & JohnsonXarelto | $66 | $8,93714 claims |
| AbbVieArmour Thyroid | $532 | $75216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Defiance
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.